Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 seroconversionDavid Simón, Georg Schett, Mario M. Zaiss et al.|Nature Communications|2020Cited by 87
Patients with immune-mediated inflammatory diseases receiving cytokine inhibitors have low prevalence of SARS-CoV-2 infectionDavid Simón, Georg Schett, Koray Taşçılar et al.|Research Square|2020Cited by 0